1011003440 (1004-12) 0810010067/J591; A Randomized Phase II Trial of 177-Lu Radio-labeled Monoclonal Antibody HuJ591 (177-Lu-J591) with Ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer after Local Therapy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Prostate Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male
  • Other:
    Histologically or cytologically confirmed adenocarcinoma of the prostate previously treated with surgery and/or radiotherapy
    Biochemical progression (rising PSA) after medical or surgical castration
    High risk of systemic progression

You may not be eligible for this study if the following are true:

  • Use of red blood cell or platelet transfusions within 4 weeks of treatment
    Use of hematopoietic growth factors within 4 weeks of treatment
    Active serious infection
    History of deep vein thrombosis and/or pulmonary embolus within 3 months of study entry
    Known history of HIV.
    Currently active other malignancy other than non-melanoma skin cancer.

Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.